cAMP 通路与肾上腺皮质发育和生长的调控。
The cAMP pathway and the control of adrenocortical development and growth.
机构信息
CNRS UMR6247, INSERM U931, Génétique Reproduction et Développement, Clermont Université, Aubière, France.
出版信息
Mol Cell Endocrinol. 2012 Mar 31;351(1):28-36. doi: 10.1016/j.mce.2011.10.006. Epub 2011 Oct 15.
Abstract
In the last 10 years, extensive studies showed that the cAMP pathway is deregulated in patients suffering from adrenocortical tumours, and particularly in primary pigmented nodular adrenocortical disease (PPNAD). Here we describe how evidence arising from the analysis of patients' data, mouse models and in vitro experiments, have shed light on the cAMP pathway as a central player in adrenal physiopathology. We also show how novel data generated from mouse models may point to new targets for potential therapies.
摘要
在过去的 10 年中，大量研究表明，cAMP 通路在患有肾上腺皮质肿瘤的患者中失调，特别是在原发性色素性结节性肾上腺皮质疾病（PPNAD）中。在这里，我们描述了从患者数据分析、小鼠模型和体外实验中获得的证据如何揭示 cAMP 通路作为肾上腺病理生理学的核心参与者。我们还展示了从小鼠模型中获得的新数据如何可能指向潜在治疗的新靶点。
相似文献
1
The cAMP pathway and the control of adrenocortical development and growth.
Mol Cell Endocrinol. 2012 Mar 31;351(1):28-36. doi: 10.1016/j.mce.2011.10.006. Epub 2011 Oct 15.
2
How does cAMP/protein kinase A signaling lead to tumors in the adrenal cortex and other tissues?
Mol Cell Endocrinol. 2011 Apr 10;336(1-2):162-8. doi: 10.1016/j.mce.2010.11.018. Epub 2010 Nov 25.
3
cAMP pathway alterations from the cell surface to the nucleus in adrenocortical tumors.
Endocr Res. 2002 Nov;28(4):765-75. doi: 10.1081/erc-120017071.
4
New genes and/or molecular pathways associated with adrenal hyperplasias and related adrenocortical tumors.
Mol Cell Endocrinol. 2009 Mar 5;300(1-2):152-7. doi: 10.1016/j.mce.2008.11.010. Epub 2008 Nov 21.
5
Cortisol-secreting adrenocortical tumours in dogs and their relevance for human medicine.
Mol Cell Endocrinol. 2016 Feb 5;421:34-9. doi: 10.1016/j.mce.2015.06.026. Epub 2015 Jun 27.
6
Activation of cyclic AMP signaling leads to different pathway alterations in lesions of the adrenal cortex caused by germline PRKAR1A defects versus those due to somatic GNAS mutations.
J Clin Endocrinol Metab. 2012 Apr;97(4):E687-93. doi: 10.1210/jc.2011-3000. Epub 2012 Jan 18.
7
Cyclic AMP-dependent signaling aberrations in macronodular adrenal disease.
Ann N Y Acad Sci. 2002 Jun;968:240-55. doi: 10.1111/j.1749-6632.2002.tb04339.x.
8
Expression of progesterone and estradiol receptors in normal adrenal cortex, adrenocortical tumors, and primary pigmented nodular adrenocortical disease.
Endocr Relat Cancer. 2008 Jun;15(2):465-74. doi: 10.1677/ERC-07-0081.
9
Detection of somatic beta-catenin mutations in primary pigmented nodular adrenocortical disease (PPNAD).
Clin Endocrinol (Oxf). 2008 Sep;69(3):367-73. doi: 10.1111/j.1365-2265.2008.03273.x. Epub 2008 Apr 14.
10
Inhibins and activins: their roles in the adrenal gland and the development of adrenocortical tumors.
Mol Cell Endocrinol. 2012 Aug 15;359(1-2):92-100. doi: 10.1016/j.mce.2011.06.005. Epub 2011 Jun 22.
引用本文的文献
1
The Emerging Role of Aldosterone Synthase Inhibitors in Overcoming Renin-Angiotensin-Aldosterone System Therapy Limitations: A Narrative Review.
Card Fail Rev. 2025 Aug 18;11:e20. doi: 10.15420/cfr.2025.09. eCollection 2025.
2
Overview of endocrine tumor syndromes manifesting as adrenal tumors.
Ewha Med J. 2024 Jan;47(1):e4. doi: 10.12771/emj.2024.e4. Epub 2024 Jan 31.
3
Editorial: Cyclic nucleotide phosphodiesterases (PDEs) signaling in the endocrine system.
Front Endocrinol (Lausanne). 2025 Jan 29;16:1548972. doi: 10.3389/fendo.2025.1548972. eCollection 2025.
4
Current insight into the transient X-zone in the adrenal gland cortex.
Vitam Horm. 2024;124:297-339. doi: 10.1016/bs.vh.2023.05.003. Epub 2023 Jul 12.
5
Disorders of the adrenal cortex: Genetic and molecular aspects.
Front Endocrinol (Lausanne). 2022 Aug 29;13:931389. doi: 10.3389/fendo.2022.931389. eCollection 2022.
6
Adrenal cortex renewal in health and disease.
Nat Rev Endocrinol. 2021 Jul;17(7):421-434. doi: 10.1038/s41574-021-00491-4. Epub 2021 May 19.
7
Aldosterone-Regulating Receptors and Aldosterone-Driver Somatic Mutations.
Front Endocrinol (Lausanne). 2021 Mar 16;12:644382. doi: 10.3389/fendo.2021.644382. eCollection 2021.
8
Cushing Syndrome in a Pediatric Patient With a KCNJ5 Variant and Successful Treatment With Low-dose Ketoconazole.
J Clin Endocrinol Metab. 2021 May 13;106(6):1606-1616. doi: 10.1210/clinem/dgab118.
9
STARD1 Functions in Mitochondrial Cholesterol Metabolism and Nascent HDL Formation. Gene Expression and Molecular mRNA Imaging Show Novel Splicing and a 1:1 Mitochondrial Association.
Front Endocrinol (Lausanne). 2020 Oct 20;11:559674. doi: 10.3389/fendo.2020.559674. eCollection 2020.
10
ARMC5 variants in PRKAR1A-mutated patients modify cortisol levels and Cushing's syndrome.
Endocr Relat Cancer. 2020 Sep;27(9):509-517. doi: 10.1530/ERC-20-0273.
本文引用的文献
1
The physiology and biochemistry of adrenarche.
Endocr Dev. 2011;20:20-27. doi: 10.1159/000321209. Epub 2010 Dec 16.
2
mTOR: from growth signal integration to cancer, diabetes and ageing.
Nat Rev Mol Cell Biol. 2011 Jan;12(1):21-35. doi: 10.1038/nrm3025. Epub 2010 Dec 15.
3
β-catenin activation is associated with specific clinical and pathologic characteristics and a poor outcome in adrenocortical carcinoma.
Clin Cancer Res. 2011 Jan 15;17(2):328-36. doi: 10.1158/1078-0432.CCR-10-2006. Epub 2010 Nov 18.
4
Wnt/β-catenin pathway activation in adrenocortical adenomas is frequently due to somatic CTNNB1-activating mutations, which are associated with larger and nonsecreting tumors: a study in cortisol-secreting and -nonsecreting tumors.
J Clin Endocrinol Metab. 2011 Feb;96(2):E419-26. doi: 10.1210/jc.2010-1885. Epub 2010 Nov 17.
5
Frequent phosphodiesterase 11A gene (PDE11A) defects in patients with Carney complex (CNC) caused by PRKAR1A mutations: PDE11A may contribute to adrenal and testicular tumors in CNC as a modifier of the phenotype.
J Clin Endocrinol Metab. 2011 Jan;96(1):E208-14. doi: 10.1210/jc.2010-1704. Epub 2010 Nov 3.
6
Cushing's syndrome and fetal features resurgence in adrenal cortex-specific Prkar1a knockout mice.
PLoS Genet. 2010 Jun 10;6(6):e1000980. doi: 10.1371/journal.pgen.1000980.
7
The potential role of mTOR inhibitors in the treatment of endocrine tumors.
J Endocrinol Invest. 2010 Apr;33(4):276-81. doi: 10.1007/BF03345792. Epub 2010 May 5.
8
Regulation of insulin-like growth factor-mammalian target of rapamycin signaling by microRNA in childhood adrenocortical tumors.
Cancer Res. 2010 Jun 1;70(11):4666-75. doi: 10.1158/0008-5472.CAN-09-3970. Epub 2010 May 18.
9
Constitutive beta-catenin activation induces adrenal hyperplasia and promotes adrenal cancer development.
Hum Mol Genet. 2010 Apr 15;19(8):1561-76. doi: 10.1093/hmg/ddq029. Epub 2010 Jan 27.
10
Shh signaling regulates adrenocortical development and identifies progenitors of steroidogenic lineages.
Proc Natl Acad Sci U S A. 2009 Dec 15;106(50):21185-90. doi: 10.1073/pnas.0909471106. Epub 2009 Dec 1.
Zotero 插件